175 related articles for article (PubMed ID: 7493357)
21. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
22. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
[TBL] [Abstract][Full Text] [Related]
23. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
24. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
[TBL] [Abstract][Full Text] [Related]
25. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
[TBL] [Abstract][Full Text] [Related]
28. Radioimmunotherapy of human B-cell chronic lymphocytic leukemia in nude mice.
Zhu Z; Ghose T; Hoskin D; Lee CL; Fernandez LA; Lee SH; Mammen M
Cancer Res; 1994 Oct; 54(19):5111-7. PubMed ID: 7923127
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2.
Li L; Xu HY; Mi L; Bian HJ; Qin J; Xiong H; Feng Q; Wen N; Tian R; Xu LQ; Shen XM; Tang H; Chen ZN
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1238-44. PubMed ID: 16979831
[TBL] [Abstract][Full Text] [Related]
30. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
31. Improved iodine radiolabels for monoclonal antibody therapy.
Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
[TBL] [Abstract][Full Text] [Related]
32. Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications.
Arano Y; Wakisaka K; Ohmono Y; Uezono T; Akizawa H; Nakayama M; Sakahara H; Tanaka C; Konishi J; Yokoyama A
Bioconjug Chem; 1996; 7(6):628-37. PubMed ID: 8950481
[TBL] [Abstract][Full Text] [Related]
33. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
Goel A; Augustine S; Baranowska-Kortylewicz J; Colcher D; Booth BJ; Pavlinkova G; Tempero M; Batra SK
Clin Cancer Res; 2001 Jan; 7(1):175-84. PubMed ID: 11205906
[TBL] [Abstract][Full Text] [Related]
34. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
35. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer.
Dean CJ; Eccles SA; Valeri M; Box G; Allan S; McFarlane C; Sandle J; Styles J
Cell Biophys; 1993; 22(1-3):111-27. PubMed ID: 7534210
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
[TBL] [Abstract][Full Text] [Related]
37. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody.
Simonson RB; Ultee ME; Hauler JA; Alvarez VL
Cancer Res; 1990 Feb; 50(3 Suppl):985s-988s. PubMed ID: 2297751
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
40. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
